Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the baltimore longitudinal study on aging: Impact on renal drug dosing

Pharmacotherapy

Volumn 33, Issue 9, 2013, Pages 912-921

  Dowling, Thomas C ^a   Wang, En Shih ^a   Ferrucci, Luigi ^b   Sorkin, John D ^c,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

BLSA; Creatinine clearance; Drug safety; Geriatrics; GFR; Glomerular filtration rate

Indexed keywords

CREATININE;

AGED; AGING; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE EPIDEMIOLOGY COLLABORATION EQUATION; COCKCROFT GAULT EQUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; MEASUREMENT PRECISION; MODIFICATION OF DIET IN RENAL DISEASE EQUATION; OBESITY;

BLSA; CREATININE CLEARANCE; DRUG SAFETY; GERIATRICS; GFR; GLOMERULAR FILTRATION RATE;

AGED; AGED, 80 AND OVER; AGING; ALGORITHMS; BALTIMORE; BIOMARKERS, PHARMACOLOGICAL; CREATININE; CROSS-SECTIONAL STUDIES; DRUG DOSAGE CALCULATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; MEDICATION ERRORS; PHARMACEUTICAL PREPARATIONS;

EID: 84880867914     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1282     Document Type: Article

References (50)

1. Agrawal V, Jaar BG, Frisby XY, et al. Access to health care among adults evaluated for CKD: findings from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2012;59(3 Suppl 2):S5-15
2. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002;13(5):1338-49
3. Families USA. Cost overdose: growth in drug spending for the elderly, 1992-2010. Available from http://familiesusa2.org/ assets/pdfs/drugod852b.pdf. Accessed June 25, 2012
4. Papaioannou A, Clarke JA, Campbell G, et al. Assessment of adherence to renal dosing guidelines in long-term care facilities. J Am Geriatr Soc 2000;48:1470-3
5. Breton G, Froissart M, Janus N, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function - the Three-City population-based study. Nephrol Dial Transplant 2011;26(9):2852-9
6. Hanlon JT, Wang X, Handler SM, et al. Potentially inappropriate prescribing of primarily renally cleared medications for older veterans affairs nursing home patients. J Am Med Dir Assoc 2011;12(5):377-83
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41
8. Dowling TC, Matzke GR, Murphy JE, Burckart GJ. Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches. Pharmacotherapy 2010;30(8): 776-86
9. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145(4):247-54
10. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150 (9):604-12
11. Melloni C, Peterson ED, Chen AY, et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2008;51 (10):991-6
12. Denetclaw TH, Oshima N, Dowling TC. Dofetilide dose calculation errors in elderly associated with use of the modification of diet in renal disease equation. Ann Pharmacother 2011;45 (7-8):e44
13. NKDEP. Chronic kidney disease and drug dosing: information for providers. 2010. Available from http://www.nkdep.nih. gov/professionals/CKD-DrugDosing- 508.pdf. Accessed July 12, 2012
14. Smythe M, Hoffman J, Kizy K, Dmuchowski C. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm 1994;51(2):198-204
15. Dooley MJ, Singh S, Rischin D. Rounding of low serum creatinine levels and consequent impact on accuracy of bedside estimates of renal function in cancer patients. Br J Cancer 2004;90(5):991-5
16. Shock NW, Greulich RC, Andres R, et al. Normal human aging: the Baltimore longitudinal study of aging. Washington, DC: U.S. Government Printing Office, 1984
17. Lalonde RL, Wagner JA. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Clin Pharmacol Ther 2009;86(5):557-61
18. Spruill WJ, Wade WE, Cobb HH 3rd. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother 2008;6(3):153-60
19. Wolowich WR, Raymo L, Rodriguez JC. Problems with the use of the modified diet in renal disease formula to estimate renal function. Pharmacotherapy 2005;25(9):1283-4
20. Dowling TC, Matzke GR, Murphy JE. Estimated GFR vs creatinine clearance for drug dosing. Am J Kidney Dis 2009;54 (5):984-5
21. Park EJ, Wu K, Mi Z, et al. A systematic comparison of Cockcroft- Gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment. Ann Pharmacother 2012;46:1174-87
22. Giannelli SV, Graf CE, Herrmann FR, et al. Natural history of older adults with impaired kidney function: the InCHIANTI study. Rejuvenation Res 2011;14(5):513-23
23. Sesso R, Prado F, Vicioso B, Ramos LR. Prospective study of progression of kidney dysfunction in community-dwelling older adults. Nephrology (Carlton) 2008;13(2):99-103
24. Andro M, Estivin S, Comps E, Gentric A. Assessment of renal function in elderly after eighty years: Cockroft and Gault or modification of diet in renal disease equation? Rev Med Interne 2011;32(11):698-702
25. Roblin I, De Sobarnitsky S, Basselin C, et al. Estimated glomerular filtration rate for drug dose adjustment: Cockcroft and Gault or abbreviated MDRD equation? Clin Biochem 2009;42(1-2):111-3
26. Pequignot R, Belmin J, Chauvelier S, et al. Renal function in older hospital patients is more accurately estimated using the Cockcroft-Gault formula than the modification diet in renal disease formula. J Am Geriatr Soc 2009;57(9):1638-43
27. Henann NE, Carpenter DU, Janda SM. Famotidine-associated mental confusion in elderly patients. Drug Intell Clin Pharm 1988;22:976-8
28. Odeh M, Oliven A. Central nervous system reactions associated with famotidine: report of five cases. J Clin Gastroenterol 1998;27:253-4
29. Wargo KA, Eiland EH 3rd, Hamm W, et al. Comparison of the modification of diet in renal disease and Cockcroft-Gault equations for antimicrobial dosage adjustments. Ann Pharmacother 2006;40(7-8):1248-53
30. Golik MV, Lawrence KR. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and modification of diet in renal disease. Pharmacotherapy 2008;28(9):1125-32
31. Gill J, Malyuk R, Djurdjev O, Levin A. Use of GFR equations to adjust drug doses in an elderly multi-ethnic group - a cautionary tale. Nephrol Dial Transplant 2007;22:2894-9
32. Hermsen ED, Maiefski M, Florescu MC, et al. Comparison of the modification of diet in renal disease and Cockcroft-Gault equations for dosing antimicrobials. Pharmacotherapy 2009;29 (6):649-55
33. Stevens LA, Nolin TD, Richardson MM. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009;54 (1):33-42
34. Food and Drug Administration (FDA). Renal impairment guidance: guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis and impact on dosing and labeling. Bethesda, MD: FDA, 2010. Available from http://www.fda.gov /downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM2049 59.pdf. Accessed December 26, 2012
35. Kwong YT, Stevens LA, Selvin E, et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. Am J Kidney Dis 2010;56:39-49
36. Moranville MP, Jennings HR. Implications of using modification of diet in renal disease versus Cockcroft-Gault equations for renal dosing adjustments. Am J Health Syst Pharm 2009;66 (2):154-61
37. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Lowmolecular- weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009;43(6):1064-83
38. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single- centre study. Clin Pharmacokinet 2010;49(4):259-68
39. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (dabigatran etexilate) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2012
40. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376(9745):975-83
41. Boehringer Ingelheim. Pradaxa (dabigatran etexilate): advisory committee briefing document. August 27, 2010. Available at http://www.fda.gov/downloads/ Advisory Committees/CommitteesMeetingMaterials/ Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/ UCM247244.pdf. Accessed June 25, 2012
42. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171(14):1285-6
43. Freshour JE, Hudson JQ, Stevens AB, Franks AS. Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance. Am J Health Syst Pharm 2012;69 (14):1184-6
44. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012;46(4):e10
45. Acorda Therapeutics, Inc. Ampyra (dalfampridine) prescribing information. Hawthorne, NY: Acorda Therapeutics, Inc., 2010
46. Smith W, Swan S, Marbury T, et al. Single-dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010;50:151-9
47. US FDA. Ampyra (dalfampridine): drug safety communication - seizure risk for multiple sclerosis patients. Rockville, MD: US FDA. Available at http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm 313055.htm. Accessed January 3, 2013
48. Siddique SM, Shariff N, Vesuwala N, Hafiz T. Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. Ann Intern Med 2009;150(7):502-4
49. Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc 2004;44 (6):661-5
50. Bauer JH, Brooks CS, Burch RN. Renal function studies in man with advanced renal insufficiency. Am J Kidney Dis 1982;2(1):30-5